Catalent Inc Stock News

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executi

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 20

Syringe maker Catalent (CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%.

Catalent, Inc. (NYSE:CTLT ) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President of Investor Relations John Greisch - Executive Chair of Boar

Catalent shares added more than 11% after the contract drugmaker's preliminary first quarter earnings topped expectations and it reaffirmed its full-year fiscal 2024 guidance. For the quarter ended i

Contract drug manufacturer Catalent on Wednesday beat Wall Street estimates for quarterly revenue as production showed signs of improvement on the back of a change in management.

Tuesday morning economic news did not include big changes in either the consumer confidence index, down about 1.5 points month over month but still above 100, or the employment cost index, up by 1.1%,

Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended Ju

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filin

The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.